UCI: Adverse Analytical Finding for Remy di Gregorio
Apr 11 2018 11:26 pm CET
UCI logo
Cycling's global governing body UCI has announced that French rider Remy di Gregorio of Delko-Marseille Provence-KTM was notified of an Adverse Analytical Finding of darbepoetin.
The sample was collected on March 8 of 2018, when the rider was participating in Paris-Nice.
Darbepoetin (dEPO) falls under "Peptide Hormones, Growth Factors, Related Substances and Mimetics", as the UCI explains.
"This intelligence-led doping control was planned and carried out by the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the UCI, in charge of defining and implementing the anti-doping strategy in cycling, with the collaboration of the Agence Française de Lutte contre le Dopage (AFLD) and the Office central de lutte contre les atteintes à l’environnement et à la santé publique (OCLAESP)," the UCI statement read.
Di Gregorio has the right to request the analysis of a B sample and has been provisionally suspended until the conclusion of the case.
The Frenchman finished 22nd in the overall classification of Paris-Nice. A month earlier, he won a stage in the Tour la Provence, his first win (excluding mountain classifications) on the European Tour since 2013.
SUBSCRIBE TO RSS FEEDS
